Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

<p>Consort diagram of the study.Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.</p>

Kaydedildi:
Detaylı Bibliyografya
Yazar: Carlotta Antoniotti (15352506) (author)
Diğer Yazarlar: Alessandra Boccaccino (15352509) (author), Robert Seitz (15352512) (author), Mirella Giordano (15352515) (author), Aurélie Catteau (15352518) (author), Daniele Rossini (15086287) (author), Filippo Pietrantonio (15035729) (author), Lisa Salvatore (15352521) (author), Kimberly McGregor (15352524) (author), Francesca Bergamo (15352527) (author), Veronica Conca (15352530) (author), Simone Leonetti (15352533) (author), Federica Morano (14937009) (author), Giorgio Papiani (15352536) (author), Emiliano Tamburini (15352539) (author), Maria Bensi (15352542) (author), Sabina Murgioni (15352545) (author), Douglas Teller Ross (15352548) (author), Alessandro Passardi (15352551) (author), Isabelle Boquet (15352554) (author), Tyler J. Nielsen (15352557) (author), Jérôme Galon (15031113) (author), Matthew Gordon Varga (15352560) (author), Brock L. Schweitzer (15352563) (author), Chiara Cremolini (15352566) (author)
Baskı/Yayın Bilgisi: 2025
Konular:
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
_version_ 1849927633357242368
author Carlotta Antoniotti (15352506)
author2 Alessandra Boccaccino (15352509)
Robert Seitz (15352512)
Mirella Giordano (15352515)
Aurélie Catteau (15352518)
Daniele Rossini (15086287)
Filippo Pietrantonio (15035729)
Lisa Salvatore (15352521)
Kimberly McGregor (15352524)
Francesca Bergamo (15352527)
Veronica Conca (15352530)
Simone Leonetti (15352533)
Federica Morano (14937009)
Giorgio Papiani (15352536)
Emiliano Tamburini (15352539)
Maria Bensi (15352542)
Sabina Murgioni (15352545)
Douglas Teller Ross (15352548)
Alessandro Passardi (15352551)
Isabelle Boquet (15352554)
Tyler J. Nielsen (15352557)
Jérôme Galon (15031113)
Matthew Gordon Varga (15352560)
Brock L. Schweitzer (15352563)
Chiara Cremolini (15352566)
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author_facet Carlotta Antoniotti (15352506)
Alessandra Boccaccino (15352509)
Robert Seitz (15352512)
Mirella Giordano (15352515)
Aurélie Catteau (15352518)
Daniele Rossini (15086287)
Filippo Pietrantonio (15035729)
Lisa Salvatore (15352521)
Kimberly McGregor (15352524)
Francesca Bergamo (15352527)
Veronica Conca (15352530)
Simone Leonetti (15352533)
Federica Morano (14937009)
Giorgio Papiani (15352536)
Emiliano Tamburini (15352539)
Maria Bensi (15352542)
Sabina Murgioni (15352545)
Douglas Teller Ross (15352548)
Alessandro Passardi (15352551)
Isabelle Boquet (15352554)
Tyler J. Nielsen (15352557)
Jérôme Galon (15031113)
Matthew Gordon Varga (15352560)
Brock L. Schweitzer (15352563)
Chiara Cremolini (15352566)
author_role author
dc.creator.none.fl_str_mv Carlotta Antoniotti (15352506)
Alessandra Boccaccino (15352509)
Robert Seitz (15352512)
Mirella Giordano (15352515)
Aurélie Catteau (15352518)
Daniele Rossini (15086287)
Filippo Pietrantonio (15035729)
Lisa Salvatore (15352521)
Kimberly McGregor (15352524)
Francesca Bergamo (15352527)
Veronica Conca (15352530)
Simone Leonetti (15352533)
Federica Morano (14937009)
Giorgio Papiani (15352536)
Emiliano Tamburini (15352539)
Maria Bensi (15352542)
Sabina Murgioni (15352545)
Douglas Teller Ross (15352548)
Alessandro Passardi (15352551)
Isabelle Boquet (15352554)
Tyler J. Nielsen (15352557)
Jérôme Galon (15031113)
Matthew Gordon Varga (15352560)
Brock L. Schweitzer (15352563)
Chiara Cremolini (15352566)
dc.date.none.fl_str_mv 2025-11-25T13:04:58Z
dc.identifier.none.fl_str_mv 10.1158/1078-0432.30707231
dc.relation.none.fl_str_mv https://figshare.com/articles/figure/Supplementary_Figure_S1_from_An_Immune-Related_Gene_Expression_Signature_Predicts_Benefit_from_Adding_Atezolizumab_to_FOLFOXIRI_plus_Bevacizumab_in_Metastatic_Colorectal_Cancer/30707231
dc.rights.none.fl_str_mv CC BY
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Cancer
Tumor Biology
Cancer Detection and Diagnosis
Therapeutic Research and Development
Immuno-oncology
Biomarkers
Gastrointestinal Cancers
Colorectal cancer
Immunotherapy
Biomarkers for immunotherapy
Translational Research
Tumor Microenvironment
Immune cells and the microenvironment
dc.title.none.fl_str_mv Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
dc.type.none.fl_str_mv Image
Figure
info:eu-repo/semantics/publishedVersion
image
description <p>Consort diagram of the study.Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.</p>
eu_rights_str_mv openAccess
id Manara_f782d85183d40bc2b0f5fd7704efc3ee
identifier_str_mv 10.1158/1078-0432.30707231
network_acronym_str Manara
network_name_str ManaraRepo
oai_identifier_str oai:figshare.com:article/30707231
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY
spelling Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal CancerCarlotta Antoniotti (15352506)Alessandra Boccaccino (15352509)Robert Seitz (15352512)Mirella Giordano (15352515)Aurélie Catteau (15352518)Daniele Rossini (15086287)Filippo Pietrantonio (15035729)Lisa Salvatore (15352521)Kimberly McGregor (15352524)Francesca Bergamo (15352527)Veronica Conca (15352530)Simone Leonetti (15352533)Federica Morano (14937009)Giorgio Papiani (15352536)Emiliano Tamburini (15352539)Maria Bensi (15352542)Sabina Murgioni (15352545)Douglas Teller Ross (15352548)Alessandro Passardi (15352551)Isabelle Boquet (15352554)Tyler J. Nielsen (15352557)Jérôme Galon (15031113)Matthew Gordon Varga (15352560)Brock L. Schweitzer (15352563)Chiara Cremolini (15352566)CancerTumor BiologyCancer Detection and DiagnosisTherapeutic Research and DevelopmentImmuno-oncologyBiomarkersGastrointestinal CancersColorectal cancerImmunotherapyBiomarkers for immunotherapyTranslational ResearchTumor MicroenvironmentImmune cells and the microenvironment<p>Consort diagram of the study.Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.</p>2025-11-25T13:04:58ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30707231https://figshare.com/articles/figure/Supplementary_Figure_S1_from_An_Immune-Related_Gene_Expression_Signature_Predicts_Benefit_from_Adding_Atezolizumab_to_FOLFOXIRI_plus_Bevacizumab_in_Metastatic_Colorectal_Cancer/30707231CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307072312025-11-25T13:04:58Z
spellingShingle Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Carlotta Antoniotti (15352506)
Cancer
Tumor Biology
Cancer Detection and Diagnosis
Therapeutic Research and Development
Immuno-oncology
Biomarkers
Gastrointestinal Cancers
Colorectal cancer
Immunotherapy
Biomarkers for immunotherapy
Translational Research
Tumor Microenvironment
Immune cells and the microenvironment
status_str publishedVersion
title Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
title_full Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
title_fullStr Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
title_full_unstemmed Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
title_short Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
title_sort Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
topic Cancer
Tumor Biology
Cancer Detection and Diagnosis
Therapeutic Research and Development
Immuno-oncology
Biomarkers
Gastrointestinal Cancers
Colorectal cancer
Immunotherapy
Biomarkers for immunotherapy
Translational Research
Tumor Microenvironment
Immune cells and the microenvironment